New targeted therapy for colorectal cancer approved in the US
Japanese pharmaceutical giant Takeda Pharmaceutical (TYO: 4502) has received US approval for Fluzakura (fruquintinib), an oral targeted therapy for colorectal cancer. The U.S. Food and Drug Administration’s decision targets the treatment of metastatic colorectal cancer (mCRC) in patients who have already tried other options, such as chemotherapy or anti-VEGF therapy. Fluzacra, an oral and chemotherapy-free […]